PATENT CLAIM ANALYSIS

Application Number: 15865339
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "019000"]

Abstract:
A phosphodiesterase type III (PDE III) inhibitor or Ca 2+ -sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.

Claim (Index 15):
The method of  claim 8 , wherein the diuretic is selected from the group consisting of furosemide, torasemide, bumetanide, etacrynic acid, azosemide, muzolimine, piretanide, tripamide, bendroflumethazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methychlothiazide, polythiazide, trichlormethiazide, chlorthialidone, indapamide, metolazone, quinethazone, etozolin, triamteren and amiloride, and combinations thereof.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.30303
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14175175', '11087465', '12482481', '13832292', '14401943']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8018077410875382
- 35 USC 102 Novelty (BERT): 0.580883174547969
- Combined Prediction Score: 0.7797152844335813
- Mean Citation Score: 413.59645200000006
- Max Citation Score: 481.5739
- Similarity Product: 407.5168134011447

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test